Histamine & Bradykinin Pharmacology · Module 3 of 4

H2 Blockers and Gastric Acid Pharmacology

Parietal cell signaling, H2 blocker comparison, and cimetidine adverse effects

Histamine is the final common amplifier of all three stimuli to parietal cell acid secretion — gastrin and acetylcholine both stimulate ECL cells to release histamine paracrine onto parietal cell H2 receptors; histamine then acts directly on parietal H2 (Gs → ↑cAMP → PKA → H⁺/K⁺-ATPase → acid); because histamine amplifies all three pathways, H2 receptor blockade reduces acid secretion driven by histamine, gastrin, AND acetylcholine — not just histamine-stimulated secretion; this is why H2 blockers are broadly effective acid suppressants despite targeting a single receptor.
H2 blockers are competitive reversible antagonists — their inhibition can be overcome by high histamine concentrations; proton pump inhibitors irreversibly inhibit H⁺/K⁺-ATPase at the final common step and produce near-complete suppression regardless of upstream stimulation; for erosive esophagitis, Zollinger-Ellison syndrome, and H. pylori eradication: PPIs are first-line; H2 blockers are appropriate for mild-to-moderate GERD without erosions and uncomplicated PUD; PPIs are required to heal erosive disease.
Cimetidine is distinguished from all other H2 blockers by two high-yield toxicities — (1) CYP450 inhibition via imidazole ring binding to heme iron: elevates warfarin (↑INR → bleeding), phenytoin (toxicity: nystagmus, ataxia), and theophylline (narrow therapeutic index → arrhythmias, seizures); famotidine and nizatidine do NOT inhibit CYP450; (2) androgen receptor antagonism: gynecomastia and impotence in men; reversible on discontinuation; correct response in both cases = switch to famotidine.
Famotidine is the preferred H2 blocker — highest potency; no CYP450 inhibition; no antiandrogenic effects; renally eliminated (dose reduction in renal impairment); ranitidine was withdrawn from the US market in 2020 due to NDMA (N-nitrosodimethylamine) contamination — a probable carcinogen generated during storage degradation; nizatidine: similar to famotidine, intermediate potency, lower Step 1 yield.
H2 blockers play an adjunctive role in anaphylaxis alongside H1 blockers — H2 receptors on cardiac myocytes and some vascular beds contribute to anaphylactic tachycardia and vasodilation; combined H1 + H2 blockade provides broader histamine receptor coverage than H1 alone; standard adjunct: diphenhydramine + famotidine; epinephrine remains the only first-line treatment; corticosteroids given as adjuncts (delayed onset; suppress late-phase response); glucagon used for beta-blocker-refractory bronchospasm (activates adenylyl cyclase independent of beta-receptor).

Abbreviations: H2 = histamine receptor 2 · ECL = enterochromaffin-like cells · CCK-2 = cholecystokinin-2 receptor · M3 = muscarinic receptor 3 · Gs = G protein s-alpha · cAMP = cyclic adenosine monophosphate · PKA = protein kinase A · PPI = proton pump inhibitor · CYP = cytochrome P450 · INR = international normalized ratio · NDMA = N-nitrosodimethylamine · GERD = gastroesophageal reflux disease · PUD = peptic ulcer disease · ZES = Zollinger-Ellison syndrome

H2 Blocker Agent Comparison

Drug	Potency	CYP450 Inhibition	Antiandrogenic	Notes
Cimetidine	Low	Yes — warfarin (↑INR/bleeding), phenytoin (↑levels/toxicity), theophylline (↑levels → arrhythmias/seizures); imidazole ring binds heme iron	Yes — gynecomastia, impotence; reversible on discontinuation; direct androgen receptor antagonism	First agent; rarely used now; switch to famotidine to resolve both toxicities
Famotidine	Highest	None	None	Preferred agent; renally eliminated (dose reduce in renal impairment); used as adjunct in anaphylaxis
Ranitidine	Intermediate	Minimal	None	Withdrawn from US market 2020 — NDMA contamination (probable carcinogen generated during storage degradation)
Nizatidine	Intermediate	None	None	Similar to famotidine; lower Step 1 yield

Cimetidine — Unique Adverse Effects

Drug Interactions — CYP450 Inhibition

Three High-Yield Pairs

Mechanism: imidazole ring binds heme iron of multiple CYP450 enzymes → broad inhibition → ↑plasma levels of co-administered drugs
Warfarin: ↑plasma levels → ↑INR → bleeding; reduce warfarin dose and monitor
Phenytoin: ↑plasma levels → toxicity (nystagmus, ataxia, confusion)
Theophylline: ↑plasma levels → narrow therapeutic index; toxicity: nausea, arrhythmias, seizures
Fix: switch to famotidine (no CYP450 inhibition)

Endocrine — Antiandrogenic

Gynecomastia and Impotence

Mechanism: cimetidine binds androgen receptors as a direct antagonist — independent of acid suppression or CYP450 inhibition
Men at therapeutic doses: gynecomastia (breast tissue enlargement) + impotence/decreased libido
Both effects reversible on discontinuation
Classic Step 1 scenario: man on long-term cimetidine for PUD develops breast enlargement
Fix: switch to famotidine (no androgen receptor affinity)

H2 Blockers vs. PPIs — When to Use Each

H2 blockers are competitive reversible H2 receptor antagonists — their inhibition can be overcome by high histamine drive. They provide partial acid suppression suitable for mild-to-moderate GERD without erosions and uncomplicated PUD maintenance. They are NOT part of H. pylori eradication regimens. Famotidine (H1 + H2 blockade combination) is an adjunct in anaphylaxis after epinephrine.

PPIs irreversibly inhibit H⁺/K⁺-ATPase at the final common step, achieving near-complete suppression regardless of upstream stimulation (histamine, gastrin, or acetylcholine levels). First-line for: erosive esophagitis (require PPI to heal), Zollinger-Ellison syndrome (high gastrin drives extreme acid output; H2 blockers may be overcome), all H. pylori eradication regimens (PPI + two antibiotics = triple therapy). Note: anaphylaxis adjunct management — epinephrine first; then H1 + H2 antihistamines (diphenhydramine + famotidine); corticosteroids for late-phase suppression (delayed onset); glucagon for beta-blocker-refractory bronchospasm (adenylyl cyclase activation independent of β-receptor).

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter on Histamine, Serotonin, and the Ergot Alkaloids	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill; 2023
Schubert ML, Peura DA.	Control of gastric acid secretion in health and disease	Gastroenterology. 2008;134(7):1842–1860
Rendic S, Di Carlo FJ.	Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors	Drug Metab Rev. 1997;29(1–2):413–580
Simons FE, Ardusso LR, Bilo MB, et al.	World Allergy Organization guidelines for the assessment and management of anaphylaxis	World Allergy Organ J. 2011;4(2):13–37
Lieberman P, Nicklas RA, Randolph C, et al.	Anaphylaxis: a practice parameter update 2015	Ann Allergy Asthma Immunol. 2015;115(5):341–384
Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A.	The kallikrein-kinin system: current and future pharmacological targets	J Pharmacol Sci. 2005;99(1):6–38
Sica DA, Gehr TWB.	Angiotensin-converting enzyme inhibitors	In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. 2nd ed. Elsevier Saunders; 2005:509–519
Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ.	Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis	Ann Allergy Asthma Immunol. 2008;101(5):495–499